Wandsy Velez, MD
Ophthalmology · Guaynabo, PRNPI 1790747855
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.0%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by AbbVie at 40.8% of the total. Reporting peaked in 2019 at $2,538 and has fallen 90.9% since, to $231 in 2025. Among ophthalmology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $195.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Romark Laboratories, LC$2K
- Alcon Puerto Rico Inc$360
- Genentech USA, Inc.$345
- Alimera Sciences, Inc.$134
- Apellis Pharmaceuticals, Inc.$125
- plus $397 from 7 others
What the payments were for
- Consulting fees$2,10037%
- Food & beverage$1,47026%
- Education$1112%
- Ownership interest$2,00035%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 8 | $2,321 |
| Romark Laboratories, LC | 1 | $2,000 |
| Alcon Puerto Rico Inc | 3 | $360 |
| Genentech USA, Inc. | 8 | $345 |
| Alimera Sciences, Inc. | 1 | $134 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| Amgen | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 1 | $94 |
| Genentech, Inc. | 1 | $83 |
| Alcon | 1 | $52 |
| Regeneron | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,682 in reported general payments places this provider in the 90th percentile of 214 ophthalmology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 37 | $23,998 |
| Alphagan PBrimonidine Tartrate | 78 | $18,500 |
| Brimonidine Tartrate | 95 | $14,977 |
| LumiganBimatoprost | 30 | $8,403 |
| AzoptBrinzolamide | 21 | $8,168 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 36 | $7,492 |
| Bromfenac Sodium | 53 | $7,327 |
| CombiganBrimonidine Tartrate/Timolol | 35 | $7,213 |
| Fluorometholone | 49 | $4,582 |
| Cyclosporine | 18 | $3,689 |
| Ketorolac Tromethamine | 116 | $3,190 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 239 | $2,886 |
| Dorzolamide Hcl | 90 | $2,695 |
| Latanoprost | 154 | $2,274 |
| Prednisolone Acetate | 52 | $2,138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Alphagan P, Lumigan, Combigan | $2,321 | $58,115180 claims |
| AlconAzopt | $52 | $8,16821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 214 ophthalmology providers in Puerto Rico.
Other ophthalmology in Guaynabo
- Carlos PouGuaynabo$3K
- Ramon BerriosGuaynabo$2K
- Maria Berrocal FernandezSan Juan$547K
- Jose MontesSan Juan$396K
- Armando OliverRio Piedras$251K
- Andres Emanuelli AnzalottaCorozal$50K
- Cristobal Cruz-ColonPonce$44K
- Juan Nevarez MarreroSan Juan$19K
- Natalio Izquierdo EncarnacionSan Juan$16K
- Ian PiovanettiSan Juan$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.